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VIRAL HEPATITIS
Apolipoprotein E and Protection Against Hepatitis E
Viral Infection in American Non-Hispanic Blacks
Lyna Zhang,1 Ajay Yesupriya,2 Man-Huei Chang,3 Eyasu Teshale,1 and Chong-Gee Teo1
Hepatitis E viral (HEV) infection imposes a heavy health burden worldwide and is common
in the United States. Previous investigations of risks addressed environmental and host behav-
ioral/lifestyle factors, but host genetic factors have not been examined. We assessed strength
of associations between antibody to HEV (anti-HEV) immunoglobulin G seropositivity indi-
cating past or recent HEV infection and human genetic variants among three major racial/
ethnic populations in the United States, involving 2434 non-Hispanic whites, 1919 non-
Hispanic blacks, and 1919 Mexican Americans from the Third National Health and Nutri-
tion Examination Survey, 1991-1994. We studied 497 single-nucleotide polymorphisms
across 190 genes (particularly those associated with lipid metabolism). The genomic control
method was used to adjust for potential population stratification. Non-Hispanic blacks had
the lowest seroprevalence of anti-HEV immunoglobulin G (15.3%, 95% confidence interval
[CI] 12.3%-19.0%) compared with non-Hispanic whites (22.3%, 95% CI 19.1%-25.7%)
and Mexican Americans (21.8%, 95% CI 19.0%-25.3%; P< 0.01). Non-Hispanic blacks
were the only population that showed association between anti-HEV seropositivity and func-
tional e3 and e4 alleles of the apolipoprotein E (APOE) gene, encoding the apolipoprotein E
protein that mediates lipoprotein metabolism. Seropositivity was significantly lower in partic-
ipants carrying APOE e4 (odds ratio5 0.5, 95% CI 0.4-0.7; P5 0.00004) and e3 (odds
ratio5 0.6, 95% CI 0.4-0.8; P5 0.001) compared to those carrying APOE e2. No significant
associations were observed between other single-nucleotide polymorphisms and anti-HEV
seropositivity in non-Hispanic blacks or between any single-nucleotide polymorphisms and
anti-HEV seropositivity in non-Hispanic whites or Mexican Americans. Conclusion: Both
APOE e3 and e4 are significantly associated with protection against HEV infection in non-
Hispanic blacks; additional studies are needed to understand the basis of protection so that
preventive services can be targeted to at-risk persons. (HEPATOLOGY 2015;62:1346-1352)
See Editorial on Page 1337
I
nfection with hepatitis E virus (HEV) can lead to
hepatitis E, a disease that is usually self-resolving but
can result in liver failure.1,2 Worldwide, of 20 mil-
lion people estimated to be HEV-infected annually,
57,000 die from liver failure.3,4 In developing countries
where waterborne HEV transmission is common, mortal-
ity is particularly high among pregnant women.5 In
industrialized countries, imported and indigenously
acquired infections occur, and chronic HEV infection is
being increasingly recognized among immunocompro-
mised persons, especially solid-organ transplant recipients
in whom progression to cirrhosis has been observed.6
A serological study of participants of the Third
National Health and Nutrition Examination Survey
Abbreviations: anti-HEV, antibody to HEV; APOA4, apolipoprotein A-IV; apoE, apolipoprotein E; CI, confidence interval; FDR, false discovery rate; GC,
genomic control; GC/FDR-P, P value adjusted for genomic control and FDR; HEV, hepatitis E virus; HSPG, heparan sulfate proteoglycan; IgG, immunoglobulin
G; NHANES III, Third National Health and Nutrition Examination Survey; OR, odds ratio; SNP, single-nucleotide polymorphism.
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(NHANES III) has suggested that one-fifth of the US
population may have been exposed to or infected by
HEV and that certain host demographic and lifestyle
factors predispose a person to HEV infection.7 Unlike
for viral hepatitis A, B, and C, human genetic risk fac-
tors for hepatitis E are not well understood.8-11 It has
been shown, however, that host-cell lipid metabolism
influences the initiation of HEV infection, replication,
and release from infected cells12,13 and that the liver is
the principal site of lipid, lipoprotein, and apolipopro-
tein metabolism; as such, patients with acute hepatitis E
show increased blood levels of apolipoprotein E
(apoE),14,15 and HEV-infected swine accumulate apoE
in the liver.16 Because human genetic variants account
for variation in lipid metabolism, genetic variations in
lipid-related genes might be associated with differential
host response to HEV infection.17 We selected candi-
date genes on the basis of their possible roles in altering
lipid and lipoprotein profiles in HEV-infected persons
and in modulating the immune response against HEV.
We determined variations in the genetic makeup of
humans potentially associated with increased risk for
HEV infection in a large candidate gene study using a
cross-sectional study of the three major racial/ethnic
populations in the United States: non-Hispanic whites,
non-Hispanic blacks, and Mexican Americans. A better
understanding of the genetic influence on susceptibility
to HEV infection can help identify and target high-risk
populations appropriate for prevention.
Methods
Ethics Statement. All data collection and labora-
tory procedures were approved by the Centers for Dis-
ease Control and Prevention’s National Center for
Health Statistics Ethics Review Board, and written
informed consent was obtained from all participants.
Though the original consent did not specifically men-
tion using stored blood specimens for future genetic
research, the National Center for Health Statistics Ethics
Review Board has approved the use of these samples for
this purpose based on the guidelines in the August 1999
National Bioethics Advisory Commission report.18 To
ensure privacy of the study participants and confiden-
tiality of their data, analysis was conducted at a secure
environment, in the National Center for Health Statis-
tics Research Data Center in Atlanta, Georgia.
Study Population. The NHANES III was con-
ducted between 1988 and 1994, and the survey design,
population, DNA bank, genotyping, and quality con-
trol have been described elsewhere.18,19 Briefly, the
NHANES III used a stratified, multistage probability
design to select subjects for household interviews, physi-
cal examinations, and laboratory tests to provide
nationally representative estimates of the health and
nutritional status of the civilian, noninstitutionalized
population aged 2 months. A DNA bank was created
from blood samples collected during the second phase
(1991-1994) from 7159 participants aged 12 years.
Genetic data were combined with behavioral, environ-
mental, and clinical information available in NHANES
III. We included in our study 6272 (87.6%) partici-
pants who self-reported as being non-Hispanic white
(n5 2434), non-Hispanic black (n5 1919), or Mexi-
can American (n5 1919, excluding Hispanic persons
of other origins) and who had been tested for antibody
to HEV (anti-HEV) immunoglobulin G (IgG). The
serostatus of participants was determined by the absence
or presence of anti-HEV IgG,7 the latter indicating past
or recent HEV infection.
Selection of Polymorphisms and Genotyping. We
selected candidate genes on the basis of their possible
roles in altering lipid and lipoprotein profiles in HEV-
infected persons and in modulating the immune
response against HEV. These genes were selected from a
candidate list (Supporting Table S1) generated from the
published literature.12-16 A total of 190 genes encom-
passing 497 single-nucleotide polymorphisms (SNPs),
genotyped through the NHANES genetic program as of
2011, were selected and are available in a restricted-
access database through the National Center for Health
Statistics Research Data Center.18 Detailed genotyping
methods and quality control criteria have been described
and are available online.18,19
Statistical Analysis. All data were weighted to the
US population in SAS-Callable SUDAAN 9.01 and
SAS 9.3.20 Weighted allele frequencies and their 95%
confidence intervals (CIs) were calculated using the
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NHANES III genetic sample weights for the 7159 par-
ticipants.19 The Taylor series linearization approach was
used to correct for the design effect and the possibility
of genetic relatedness of persons sampled from the same
household. The logistic regression model was used to
test for association between each SNP and anti-HEV
seropositivity for each race/ethnicity group.21,22 An
additive genetic model (AA versus Aa versus aa), which
treats the marker as a continuous variable, was assumed
for regression analyses to test the null hypothesis that
anti-HEV seropositivity does not vary with increasing
copy numbers of the minor allele a.
The genomic control (GC) method was used to
adjust for potential population stratification.23 Sat-
terthwaite v2 statistics generated from a supplemental
set of 267 SNPs from the NHANES III genetic data set
were used to derive empirical estimates of the null distri-
bution that accounted for the effects of population
structure (i.e., the presence of a significant difference in
allele frequencies within US racial/ethnic subpopula-
tions due to different ancestry). These SNPs were cho-
sen without any prior knowledge of associations with
anti-HEV seropositivity and to be at least 1 million base
pairs apart from each other in order to reduce the likeli-
hood that they would be in linkage disequilibrium. A list
of these SNPs is provided in Supporting Table S2. The
variance inflation factor, k (calculated as the median value
from the null distributions divided by the median value
of the theoretical v2 statistics distribution, 0.4549), was
used to readjust the Satterthwaite v2 statistics from the
regression models for SNPs in the candidate genes for
potential confounding by population structure.
The P values from the GC-corrected v2 Satterthwaite
statistics were then further adjusted for multiple testing
using the false discovery rate (FDR) as estimated by the
PROC MULTTEST procedure in SAS.24 A significant
association was defined as the GC- and FDR-adjusted P
value (GC/FDR-P)< 0.05 for all SNPs and anti-HEV
seropositivity.
Results
Descriptive Analysis. Of 7159 possible subjects,
6262 (87.5%) met the inclusion criteria (Table 1).
Table 1. Characteristics of Study Participants Who Tested Seropositive for Anti-HEV IgG in the NHANES III, 1991-1994
All Participants (n5 6272) Non-Hispanic Whites (n5 2434) Non-Hispanic Blacks (n5 1919) Mexican Americans (n5 1919)
Characteristics % (95% CI)* P† % (95% CI) P % (95% CI) P % (95% CI) P
Total 21.6 (18.6-24.4) <0.001 22.3 (19.1-25.7) 15.3 (12.3-19.0) 21.8 (19.0-25.3)
Sex
Male 22.1 (18.4-26.3) 0.43 22.8 (18.5-27.8) 0.62 15.1 (11.2-20.0) 0.83 25.5 (21.8-29.7) 0.004
Female 20.7 (18.0-23.7) 21.7 (18.6-25.2) 15.5 (12.4-19.3) 18.0 (14.6-22.1)
Age (years)
12-19 3.6 (2.2-6.6) 3.3 (1.4-7.4) 5.1 (2.9-8.7) 5.0 (3.1-7.9)
20-29 8.7 (5.6-13.3) 7.9 (4.3-514.0) 7.1 (4.3-11.5) 17.3 (12.7-23.2)
30-44 18.5 (15.1-22.4) <0.001 18.8 (14.7-23.7) <0.001 14.0 (10.7-18.2) <0.001 24.3 (21.7-27.5) <0.001
45-64 33.3 (28.0-39.1) 33.6 (27.4-40.3) 28.3 (23.0-34.4) 39.4 (33.2-45.9)
65 40.4 (36.3-44.6) 41.1 (36.5-45.6) 32.6 (23.4-43.4) 44.0 (34.9-53.5)
Country of birth‡
United States 20.3 (17.4-23.6) <0.001 21.5 (18.2-25.2) <0.001 15.4 (12.3-19.1) 0.8 10.2 (8.6-11.9) <0.001
Foreign-born 32.0 (27.3 237.1) 35.9 (26.6-46.4) 14.0 (6.2-28.6) 32.5 (28.5-36.8)
Region of residence§
Northeast 21.3 (14.1-31.0) 22.1 (14.0-33.1) 14.4 (11.6-17.7) 28.8 (11.3-56.2)
Midwest 24.9 (20.1-30.2) 0.009 25.2 (20.6-30.4) 0.01 21.4 (13.5-32.1) 0.33 25.7 (22.7-29.0) 0.02
West 24.7 (18.8-31.8) 14.8 (11.6-18.7) 13.8 (9.8-19.1) 15.7 (11.6-20.8)
South 14.6 (11.7-18.2) 25.8 (18.4-35.0) 13.2 (9.8-17.6) 23.7 (20.2-27.5)
Poverty income ratiok
>1 22.2 (19.3-25.5) 0.02 23.0 (19.8-26.6) 0.01 15.4 (12.5-18.8) 0.83 20.6 (17.5-24.0) 0.08
1 17.9 (14.7-21.7) 17.3 (13.6-21.6) 15.9 (10.7-23.0) 23.7 (19.8-28.2)
Education (years)
<12 19.1 (15.9-22.7) 0.01 18.7 (14.7-23.6) 0.02 15.3 (11.6-20.0) 0.9 25.4 (22.3-28.8) <0.001
12 22.3 (19.5-25.3) 23.4 (20.3-26.7) 15.3 (12.4-18.8) 16.0 (13.2-19.4)
*Frequencies were adjusted using NHANES III genetic sample weights.
†P value was calculated using the Wald chi-squared test based on the log OR. Having a pet in the home (P5 0.5); consuming liver or other organ meats
(P5 0.27); and levels of alanine aminotransferase (P5 0.92), aspartate aminotransferase (P5 0.1), and C-reactive protein (P5 0.07) were not associated with
increased odds of anti-HEV seropositivity.
‡Persons born outside of the United States and its territories were considered foreign-born.
§Region was defined using standard Census Bureau groupings.
kPoverty income ratio was calculated by dividing the total family income by the poverty threshold adjusted for family size at year of interview. Values <1 were
considered below the poverty line.
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Overall, the seropositivity rate was 21.6% in participants
aged 12 years, which varied significantly among the
three racial/ethnic populations (P< 0.01). It was lower
among non-Hispanic blacks (15.3%, 95% CI 12.3%-
19.0%) compared with non-Hispanic whites (22.3%,
95% CI and 19.1%-25.7%) or Mexican Americans
(21.8%, 95% CI 19.0%-25.3%). Seropositivity was
strongly associated with age, rising significantly with
increasing age across all three subpopulations and peaking
in the>65-year age group. Seropositivity was significantly
associated with region of residence, poverty income ratio,
education attained, and country of birth (Table 1).
Genetic Associations With Anti-HEV Seropositivity.
Among the SNPs, 98% were significantly different in
allele frequency across race/ethnicity groups (P< 0.01)
(data not shown). The extent of this differentiation var-
ied greatly between SNPs and between racial/ethnic
populations. Accordingly, we conducted three parallel
analyses, one for each race/ethnicity group for each SNP
tested. Excluded were SNPs with a minor allele fre-
quency <1% or a major allele frequency >99%. In the
final analysis, 459, 491, and 469 SNPs were included
for non-Hispanic whites, non-Hispanic blacks, and
Mexican Americans, respectively. The effects of using
GC on the results are shown in Supporting Fig. S1. The
v2 value overestimation, as indicated by GC inflation
factor k, was 1.3, 1.0, and 1.8 times higher for non-
Hispanic whites, non-Hispanic blacks, and Mexican
Americans, respectively (Table 2).
The univariable analysis indicated significant genetic
associations with seropositivity and race/ethnicity
among non-Hispanic blacks but not among non-
Hispanic whites or Mexican Americans (Fig. 1). Two
SNPs, rs5110 in apolipoprotein A-IV (APOA4, located
in chromosome 11) and rs7412 in APOE (in chromo-
some 19), were associated with anti-HEV seropositivity
among non-Hispanic blacks in the univariable models.
Specifically, the alleles APOA4 rs5110-A (odds ratio
[OR]5 0.2, 95% CI 0.1-0.5; GC/FDR-P5 0.007) and
APOE rs7412-C (OR5 0.6, 95% CI 0.5-0.8; GC/
FDR-P5 0.02) were associated with lower odds of sero-
positivity (Table 2).
The APOE gene encodes the apoE protein. This pro-
tein combines with fats (lipids) in the body to form lip-
oproteins. Lipoproteins are responsible for packaging
cholesterol and other fats and carrying them through
the bloodstream. There are three apoE protein isoforms
(apoE2, apoE3, and apoE4), differing from each other
by only one or two amino acids at positions 112 and
158. These isoforms are encoded by three allelic variants
of APOE: e2, e3, and e4, respectively. Variants e2, e3,
and e4 are haplotypes defined by rs7412 and
rs429358.25 In non-Hispanic blacks APOE rs7412 was
associated with lower odds of seropositivity, and
rs429358 was not statistically significant in the overall
scan after adjustments by both the GC for potential
population stratification and the FDR for multiple test-
ing. As we were interested in these well-studied func-
tional APOE allelic variants, we further conducted
analysis on e2, e3, and e4 to determine any association
(P< 0.05) with anti-HEV seropositivity for each race/
ethnicity group. The seropositivity rate among non-
Hispanic blacks carrying e4 was significantly lower than
in those carrying e2 (OR5 0.5, 95% CI 0.4-0.7;
P5 0.00004), as was the rate in those carrying e3 com-
pared to those carrying e2 (OR5 0.6, 95% CI 0.4-0.8;
P5 0.001) (Table 3).
Discussion
We have examined associations between human
genetic variants and HEV infection in a nationally
Table 2. Associations of Genetic Variants in APOA4 and APOE Among Non-Hispanic Blacks With Anti-HEV Seropositivity in
the NHANES III, 1991-1994
Variant Allele Frequency* (%) OR (95% CI) P† GC/FDR-P‡
Non-Hispanic whites
APOA4 rs5110 (A) 92.7 0.8 (0.6-1.1) 0.17 0.99
APOE rs7412 (C) 8.4 0.9 (0.7-1.2) 0.64 0.99
Non-Hispanic blacks
APOA4 rs5110 (A) 98.3 0.2 (0.1-0.5) <0.001 0.007
APOE rs7412 (C) 10.0 0.6 (0.5-0.8) <0.001 0.02
Mexican Americans
APOA4 rs5110 (A) 94.9 1.2 (0.7-1.9) 0.53 0.99
APOE rs7412 (C) 3.3 0.9 (0.6-1.5) 0.69 0.99
*Frequencies were adjusted using NHANES III genetic sample weights.
†P value was based on logistic regression analysis using an additive genetic model within each race/ethnicity group.
‡P value was adjusted for population stratification with GC inflation factor k and multiple comparisons using the FDR in PROC MULTTEST (SAS 9.3). Inflation fac-
tor k of the GC was calculated from data of a separate set of 267 SNPs from NHANES III for each race/ethnicity group. k was 1.31, 1.02, and 1.82 for non-
Hispanic whites, non-Hispanic blacks, and Mexican Americans, respectively.
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representative sample of the three major race/ethnicity
groups in the United States. Among non-Hispanic
blacks, whose anti-HEV seroprevalence rate was lowest
compared to non-Hispanic whites and Mexican Ameri-
cans, APOE e3 and e4 were found to be significantly
associated with protection against HEV infection.
Originally recognized for its importance in lipopro-
tein metabolism and cardiovascular disease, apoE, whose
isoforms are apoE4, apoE3 and apoE2, are increasingly
known to play key roles in biological processes in addi-
tion to lipid transport, such as cognitive function and
immunoregulation.26,27 Although the isoforms differ by
single–amino acid substitutions, these changes can lead
to profound functional consequences, including vari-
ability in domain interactions, protein stability, and pro-
tein folding, which in turn can influence susceptibility
to and the natural history of disease. Thus, individuals
carrying the APOE e4 allele are reported to be 10 times
more likely to develop late-onset Alzheimer’s disease
than those carrying other variants.28
Among the non-Hispanic blacks in our study popula-
tion, the association between lower APOE e4 carriage
and seropositivity rate for anti-HEV likely reflects the
protective effect of apoE4 against primary HEV infec-
tion in the liver. Apolipoprotein E is synthesized mainly
by the liver,29 and in vitro studies have shown that
Fig. 1. Genetic associations
between anti-HEV-seropositivity
and race/ethnicity among non-
Hispanic blacks, non-Hispanic
whites and Mexican Americans
by univariable analysis.
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apoE4 exhibits greater binding affinity to cultured hepa-
toma cells than apoE3.30 Possible explanations for how
apoE influences the protection against HEV infection
include (1) HEV using the same hepatocyte entry medi-
ators as those of apoE, (2) the incorporation of apoE in
the HEV envelope, and (3) apoE modulating the
immune response against HEV.29 First, apoE is able to
bind to several cell surface receptors, including heparan
sulfate proteoglycans (HSPGs) and low-density lipopro-
tein receptors. Several pathogens, such as hepatitis C
virus,31 herpes simplex virus,32 human immunodefi-
ciency virus,33 and the malaria protozoon,34 have been
reported to bind to one or another of these receptor sites
to gain entry to target cells. Indeed, apoE can inhibit
such binding by competing with HSPGs.27,35 Also,
HSPGs have been shown to be requisite for the HEV
capsid protein to bind to facilitate cell entry,36 so any
difference in isoform affinity for HSPGs conferred by
the APOE genotype may affect the extent to which
HEV enters hepatocytes. Second, HEV virions circulat-
ing in the blood are covered with an envelope that possi-
bly incorporates apoE in the lipid membrane as it exits
from the host cell,16 similar to other enveloped viruses
(e.g., human immunodeficiency virus, hepatitis C virus,
and herpes simplex virus).37 The envelope protects the
virus against neutralizing antibodies. Moreover, being
essential for the transport of cholesterol into and out of
the liver and a critical component of the viral envelope,
apoE may be essential for viral entry and assembly.38
Third, as HEV-specific T-cell responses play critical
roles in controlling the course of HEV infection,39 apoE
may modulate the immune response against HEV by
regulating T-lymphocyte activation and proliferation.29
This study is among the first to apply the GC method
to correct for potential confounding from population
substructures in the NHANES, which may be particu-
larly important as race/ethnicity was based on self-
report. Confounding can result from stratification or
recent admixture of distinct subpopulations.40 Genetic
admixture is commonly encountered among Mexican
American and non-Hispanic black populations (sub-
stantially less among non-Hispanic whites).41,42 Given
the GC inflation factors in the current study, Mexican
Americans were most likely to be affected by population
structure, followed by non-Hispanic whites and non-
Hispanic blacks. Applying a GC, as was done in this
study, lends confidence to validating the detected
associations.
This study has several limitations. First, the outcome
of the study, seropositivity to anti-HEV IgG, is cumula-
tive without knowledge of when the antibody first
appeared, its persistence, or to which HEV genotype it
was elicited against. Second, overly conservative P values
may be generated by FDR, which may decrease our abil-
ity to identify true associations. Unlike unadjusted P val-
ues expressing the probability of a false-positive result for
a single test, the FDR gives a conservative estimate of the
proportion of false positives among variants with signifi-
cant association. Finally, the statistical power to detect
significant associations with uncommon genetic variants
was limited. Although this cross-sectional study was
adequately powered to detect in each racial/ethnic group
the two crude associations between anti-HEV seropositiv-
ity and rs5110-A or rs7412-C that were found for non-
Hispanic blacks (Supporting Table S3), the possibility
that these SNPs are proxies for true causal variants cannot
be excluded. Differences in linkage disequilibrium
between races/ethnicities thus may hamper our ability to
detect associations across all three groups, if they exist.
In conclusion, this NHANES-based cross-sectional
study found that APOE e3 and e4 may be associated
with protection against HEV infection in non-Hispanic
blacks but not non-Hispanic whites or Mexican Ameri-
cans. No other data have yet been generated to suggest
that certain individuals or populations are biologically
more resistant or susceptible to HEV infection. There-
fore, replication of our study’s findings is encouraged, as
is investigation into the functional relevance of the genes
uncovered. Discovery of the basis of protection against
HEV can inform the development of targeted preventa-
tive measures for at-risk populations.
Acknowledgment: We sincerely thank all the study
subjects who participated in NHANES III. Special
thanks to staff at the Research Data Center in the
National Center for Health Statistics for their data
support and assistance in disclosure review.
Table 3. Protective Effect of APOE Variants Against HEV
Infection in Non-Hispanic Blacks* in the NHANES III,
1991-1994
Variant Allele Frequency† (%) OR (95% CI) P
Non-Hispanic whites
APOE e2 8.3 1 (reference)
APOE e3 76.0 0.9 (0.7-1.2) 0.99
APOE e4 15.7 0.9 (0.6-1.6) 0.99
Non-Hispanic blacks
APOE e2 10.1 1 (reference)
APOE e3 67.9 0.6 (0.4-0.8) 0.001
APOE e4 22.0 0.5 (0.4-0.7) 0.00004
Mexican Americans
APOE e2 3.3 1 (reference)
APOE e3 85.7 0.9 (0.6-1.5) 0.99
APOE e4 11.0 0.8 (0.5-1.6) 0.99
*Logistic regression analysis within each race/ethnicity group.
†Frequencies adjusted using NHANES III genetic sample weight.
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